Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

@article{Bookman2009EvaluationON,
  title={Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.},
  author={Michael A. Bookman and Mark F. Brady and William Patrick McGuire and Peter G. Harper and David S. Alberts and Michael Friedlander and Nicoletta Colombo and Jeffrey M. Fowler and Peter A. Argenta and Koen de Geest and David G. Mutch and Robert A. Burger and Ann Marie C Swart and Edward Lloyd Trimble and Chrisann Accario-Winslow and Lawrence M Roth},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 9},
  pages={1419-25}
}
PURPOSE To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma who receive carboplatin and paclitaxel. PATIENTS AND METHODS Women with stages III to IV disease were stratified by coordinating center, maximal diameter of residual tumor, and intent for interval cytoreduction and were then randomly assigned among five arms… CONTINUE READING
222 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 222 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

  • W ten Bokkel Huinink, SR Lane, GA Ross
  • Ann Oncol 15:100-103,
  • 2004
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…